ACC 2020: VOYAGER PAD Results Add Valuable Knowledge to Field of Peripheral Artery Disease
The DCRI’s Manesh Patel, MD, who was a member of the steering committee for this late-breaking clinical trial, has been working for years to determine the best treatment strategies for patients with peripheral artery disease.
Updated Meta-Analysis Confirms that Patients with Atrial Fibrillation Undergoing PCI Should Avoid Triple Antithrombotic Therapy with Warfarin
Recent evidence suggests that a novel oral anticoagulant plus a P2Y12 inhibitor may be the best treatment pathway for patients with atrial fibrillation undergoing percutaneous coronary intervention. DCRI faculty contributed to a meta-analysis recently published in JAMA Cardiology, which drew data from five clinical trials, including DCRI-led AUGUSTUS, to evaluate the safety and efficacy of four different antithrombotic regimens.
Paper Details Design of ADAPTABLE, First Pragmatic Trial to Use PCORnet®
A paper recently published in JAMA Cardiology details the design of ADAPTABLE, a DCRI-led pragmatic clinical trial that uses many novel elements to efficiently answer a question that has substantial impacts on public health. ADAPTABLE seeks to determine the optimal dose of aspirin for patients with heart disease. Although aspirin has been used as a secondary prevention method for nearly three decades, the question of whether low-dose or high-dose aspirin is more beneficial remains unanswered.
Preventing Alzheimer’s Disease? Taking the First Step Through the TOMMORROW Trial
The study sought to simultaneously test a method for identifying individuals at high risk for Alzheimer’s disease while testing the efficacy of a potential treatment aimed at targets affecting cell
Patient-Reported Health Data in Pragmatic Trials: Helpful, But Not Without Limitations
A report from an NIH Health Care Systems Research Collaboratory roundtable recently published in
12-month SECURE-PCI Results add Context to Original Findings
Although initial results from SECURE-PCI suggested that patients treated with periprocedural loading doses of atorvastatin and undergoing percutaneous coronary intervention (PCI) experienced a reduced risk of major adverse cardiovascular events (MACE), extended follow-up showed no significant difference. The 12-month results, which were recently published in JAMA, expand upon the initial study, which followed patients for 30 days.
DCRI and Digital Solutions: A New World of Evidence Generation
From thought leadership on a national stage to driving adoption for digital health technologies, the DCRI is leading the way in the digital therapeutic space.
Special Considerations for Resuscitation of Older Patients
Resuscitation after out-of-hospital cardiac arrest should not be administered using a one-size-fits-all approach, especially when treating older patients, according to an editorial in
Abnormal Electrocardiography Despite Normal Stress Echocardiography Could be Warning Sign
Findings from a DCRI-led study recently published in JAMA Internal Medicine suggest new prognostic implications for patients who have abnormal exercise electrocardiography (ECG) but normal stress echocardiography (Echo) results.
In clinical practice, exercise ECG is combined with stress Echo imaging for the evaluation of coronary artery disease. Although it is not uncommon for patients to have discordant results (abnormal ECGs and normal Echos), it was previously unclear whether this had any prognostic significance for these patients. An observational study led by DCRI’s Melissa Daubert, MD, sought to answer this question.
Longitudinal Study Links Variable Blood Pressure in Young Adults to Increased Risk for Cardiovascular Disease
Two DCRI researchers contributed to a study that points to a potential early warning sign for increased risk of cardiovascular disease.